For example, transcriptome analysis of tumor biopsies from 40 melanoma patients before treatment with anti-CTLA-4 indicated higher expression of the CYT score, CTLA-4, PD-1, PD-L1, and PD-L2 in patients with clinical benefit (Van Allen et al. 2015). This evidence concerns the gene CTLA4 and melanoma.